GREEN CROSS CORP has a total of 2,399 patent applications. It increased the IP activity by 83.0%. Its first patent ever was published in 1962. It filed its patents most often in Japan, United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and machines are AVIXGEN INC, SLOAN KETTERING INST CANCER and THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES.
# | Country | Total Patents | |
---|---|---|---|
#1 | Japan | 1,036 | |
#2 | United States | 239 | |
#3 | EPO (European Patent Office) | 191 | |
#4 | Canada | 165 | |
#5 | Republic of Korea | 118 | |
#6 | WIPO (World Intellectual Property Organization) | 109 | |
#7 | Spain | 55 | |
#8 | Germany | 50 | |
#9 | China | 48 | |
#10 | United Kingdom | 45 | |
#11 | Australia | 37 | |
#12 | France | 31 | |
#13 | Switzerland | 26 | |
#14 | Sweden | 25 | |
#15 | Taiwan | 25 | |
#16 | Brazil | 23 | |
#17 | Austria | 17 | |
#18 | Hong Kong | 12 | |
#19 | South Africa | 12 | |
#20 | Belgium | 11 | |
#21 | Denmark | 11 | |
#22 | Netherlands | 11 | |
#23 | Mexico | 9 | |
#24 | Israel | 8 | |
#25 | India | 8 | |
#26 | Singapore | 8 | |
#27 | Philippines | 7 | |
#28 | Italy | 6 | |
#29 | Luxembourg | 6 | |
#30 | Finland | 5 | |
#31 | USSR (Union of Socialist Soviet Republics) | 5 | |
#32 | Chile | 4 | |
#33 | Malaysia | 4 | |
#34 | New Zealand | 4 | |
#35 | Argentina | 3 | |
#36 | EAPO (Eurasian Patent Organization) | 3 | |
#37 | Hungary | 3 | |
#38 | Peru | 3 | |
#39 | Colombia | 2 | |
#40 | German Democratic Republic | 2 | |
#41 | Norway | 2 | |
#42 | Portugal | 2 | |
#43 | Slovenia | 2 | |
#44 | Bulgaria | 1 | |
#45 | Ireland | 1 | |
#46 | Serbia | 1 | |
#47 | Russian Federation | 1 | |
#48 | Ukraine | 1 | |
#49 | Yugoslavia (Serbia and Montenegro) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Machines | |
#4 | Organic fine chemistry | |
#5 | Foods and drinks | |
#6 | Medical technology | |
#7 | Measurement | |
#8 | Basic materials chemistry |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Microorganisms | |
#5 | Unspecified technologies | |
#6 | Heterocyclic compounds | |
#7 | Enzymes | |
#8 | Object sterilising | |
#9 | Analysing materials | |
#10 | Preservation of human bodies |
# | Name | Total Patents |
---|---|---|
#1 | Yokoyama Kazumasa | 397 |
#2 | Suyama Tadakazu | 307 |
#3 | Kamimura Yatsuhiro | 154 |
#4 | Takechi Kazuo | 110 |
#5 | Nishida Masayuki | 104 |
#6 | Funakoshi Satoru | 102 |
#7 | Arimura Hirobumi | 96 |
#8 | Fukaya Tsutomu | 88 |
#9 | Funakoshi Satoshi | 85 |
#10 | Fukaya Chikara | 84 |
Publication | Filing date | Title |
---|---|---|
WO2020251187A1 | Antibody to tigit and use thereof | |
JP2020125350A | Pharmaceutical composition for inhibiting metastasis of cancer, comprising, as active ingredient, antibody that specifically binds to epidermal growth factor receptor | |
WO2020204305A1 | Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof | |
KR20200118562A | Bispecific antibody that specifically binds to gpnmb and cd3 and use thereof | |
KR102084912B1 | Conformational epitope of hepatitis b virus surface antigen and antibody specifically binding to the same | |
KR20200034321A | Highly efficient anti-TFPI antibody composition | |
BR112020006311A2 | METHOD FOR PREPARING A KNOCKOUT RABBIT OF FACTOR VIII OR FACTOR IX GENE AND USE OF THE SAME | |
KR20190136271A | Method and composition for treating hunter syndrome by administration of lateral ventricle of cerebrum | |
KR20190112982A | Method for obtaining bordetella pertussis related proteins comprising affinity chromatography | |
KR20180026688A | Composition comprising long-acting Erythropoietin | |
KR20190063765A | Anti-ceacam1 antibody and use thereof | |
KR20190047376A | Improved Method for Purification of Immunoglobulin | |
KR101973060B1 | Antibody against cd3 and pharmaceutical composition for treating cancer comprising the same | |
KR101966362B1 | Antibody against msln and pharmaceutical composition for treating cancer comprising the same | |
WO2019045149A1 | Method for purifying a sulfatase protein | |
KR20170098206A | Pharmaceutical formulation comprising anti-egfr antibody | |
KR20190013296A | Method for obtaining bordetella pertussis related protein comprising processes of freezing and thawing | |
KR20180108183A | Anti-ceacam1 antibody and use thereof | |
WO2017116066A1 | Methods and compositions for treating hunter syndrome | |
KR20180056028A | Methods for Eliminating Factor XI during Plasma Protein Purification |